(PDF) P1.16-12 Identification of a Biomarker Panel in

P1.16-12 Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit From Adjuvant Chemotherapy

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.981

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.16-47 Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report From ALCHEMIST (Alliance A151216)

Journal of Thoracic Oncology

Respiratory Medicine

English

ERCC1 as a Biomarker for Bladder Cancer Patients Likely to Benefit From Adjuvant Chemotherapy

Cancer Research

English

Polo-Like Kinase 2 Promotes Chemoresistance and Predicts Limited Survival Benefit From Adjuvant Chemotherapy in Colorectal Cancer

International Journal of Oncology

Cancer Research

English

TRAP1 Is a Predictive Biomarker of Platinum-Based Adjuvant Chemotherapy Benefits in Patients With Resected Lung Adenocarcinoma

Biomedical Research

Molecular Biology

English

High TMB Predicts Immunotherapy Benefit in NSCLC

Cancer Discovery

English

P1.09-07 PD-L1 Protein Expression Is a Predictor of Benefit From Adjuvant Chemotherapy in Resected Non-Small Cell Lung Carcinoma

Journal of Thoracic Oncology

Respiratory Medicine

English

Adjuvant Chemotherapy With Gemcitabine and Long-Term Outcomes Among Patients With Resected Pancreatic Cancer

JAMA - Journal of the American Medical Association

English

P1.16-63 the Value of Adjuvant Chemotherapy in Patients With Resected Stage IB Solid Predominant and Solid Non-Predominant Lung Adenocarcinoma

Journal of Thoracic Oncology

Respiratory Medicine

English

Comparison of Perioperative Chemotherapy and Adjuvant Chemoradiation in Resected Gastric Cancer

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English